172 related articles for article (PubMed ID: 22562771)
1. Cerebrospinal fluid amyloid-β (Aβ) as an effect biomarker for brain Aβ lowering verified by quantitative preclinical analyses.
Lu Y; Riddell D; Hajos-Korcsok E; Bales K; Wood KM; Nolan CE; Robshaw AE; Zhang L; Leung L; Becker SL; Tseng E; Barricklow J; Miller EH; Osgood S; O'Neill BT; Brodney MA; Johnson DS; Pettersson M
J Pharmacol Exp Ther; 2012 Aug; 342(2):366-75. PubMed ID: 22562771
[TBL] [Abstract][Full Text] [Related]
2. Quantitative pharmacokinetic/pharmacodynamic analyses suggest that the 129/SVE mouse is a suitable preclinical pharmacology model for identifying small-molecule γ-secretase inhibitors.
Lu Y; Zhang L; Nolan CE; Becker SL; Atchison K; Robshaw AE; Pustilnik LR; Osgood SM; Miller EH; Stepan AF; Subramanyam C; Efremov I; Hallgren AJ; Riddell D
J Pharmacol Exp Ther; 2011 Dec; 339(3):922-34. PubMed ID: 21930801
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid β-Amyloid turnover in the mouse, dog, monkey and human evaluated by systematic quantitative analyses.
Lu Y; Barton HA; Leung L; Zhang L; Hajos-Korcsok E; Nolan CE; Liu J; Becker SL; Wood KM; Robshaw AE; Taylor CK; O'Neill BT; Brodney MA; Riddell D
Neurodegener Dis; 2013; 12(1):36-50. PubMed ID: 22922480
[TBL] [Abstract][Full Text] [Related]
4. Amyloid-β(1-15/16) as a marker for γ-secretase inhibition in Alzheimer's disease.
Portelius E; Zetterberg H; Dean RA; Marcil A; Bourgeois P; Nutu M; Andreasson U; Siemers E; Mawuenyega KG; Sigurdson WC; May PC; Paul SM; Holtzman DM; Blennow K; Bateman RJ
J Alzheimers Dis; 2012; 31(2):335-41. PubMed ID: 22531418
[TBL] [Abstract][Full Text] [Related]
5. In vivo characterization of Abeta(40) changes in brain and cerebrospinal fluid using the novel gamma-secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) in the rat.
Best JD; Jay MT; Otu F; Churcher I; Reilly M; Morentin-Gutierrez P; Pattison C; Harrison T; Shearman MS; Atack JR
J Pharmacol Exp Ther; 2006 May; 317(2):786-90. PubMed ID: 16443723
[TBL] [Abstract][Full Text] [Related]
6. BIIB042, a novel γ-secretase modulator, reduces amyloidogenic Aβ isoforms in primates and rodents and plaque pathology in a mouse model of Alzheimer's disease.
Scannevin RH; Chollate S; Brennan MS; Snodgrass-Belt PA; Peng H; Xu L; Jung MY; Bussiere T; Arastu MF; Talreja T; Xin Z; Dunstan RW; Fahrer D; Rohde E; Dunah AW; Wang J; Kumaravel G; Taveras AG; Moore Arnold H; Rhodes KJ
Neuropharmacology; 2016 Apr; 103():57-68. PubMed ID: 26690893
[TBL] [Abstract][Full Text] [Related]
7. Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of Alzheimer disease.
Jeppsson F; Eketjäll S; Janson J; Karlström S; Gustavsson S; Olsson LL; Radesäter AC; Ploeger B; Cebers G; Kolmodin K; Swahn BM; von Berg S; Bueters T; Fälting J
J Biol Chem; 2012 Nov; 287(49):41245-57. PubMed ID: 23048024
[TBL] [Abstract][Full Text] [Related]
8. Spirocyclic β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors: from hit to lowering of cerebrospinal fluid (CSF) amyloid β in a higher species.
Hunt KW; Cook AW; Watts RJ; Clark CT; Vigers G; Smith D; Metcalf AT; Gunawardana IW; Burkard M; Cox AA; Geck Do MK; Dutcher D; Thomas AA; Rana S; Kallan NC; DeLisle RK; Rizzi JP; Regal K; Sammond D; Groneberg R; Siu M; Purkey H; Lyssikatos JP; Marlow A; Liu X; Tang TP
J Med Chem; 2013 Apr; 56(8):3379-403. PubMed ID: 23537249
[TBL] [Abstract][Full Text] [Related]
9. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.
Martone RL; Zhou H; Atchison K; Comery T; Xu JZ; Huang X; Gong X; Jin M; Kreft A; Harrison B; Mayer SC; Aschmies S; Gonzales C; Zaleska MM; Riddell DR; Wagner E; Lu P; Sun SC; Sonnenberg-Reines J; Oganesian A; Adkins K; Leach MW; Clarke DW; Huryn D; Abou-Gharbia M; Magolda R; Bard J; Frick G; Raje S; Forlow SB; Balliet C; Burczynski ME; Reinhart PH; Wan HI; Pangalos MN; Jacobsen JS
J Pharmacol Exp Ther; 2009 Nov; 331(2):598-608. PubMed ID: 19671883
[TBL] [Abstract][Full Text] [Related]
10. Characterization of FRM-36143 as a new γ-secretase modulator for the potential treatment of familial Alzheimer's disease.
Blain JF; Bursavich MG; Freeman EA; Hrdlicka LA; Hodgdon HE; Chen T; Costa DE; Harrison BA; Kapadnis S; Murphy DA; Nolan S; Tu Z; Tang C; Burnett DA; Patzke H; Koenig G
Alzheimers Res Ther; 2016 Aug; 8(1):34. PubMed ID: 27572246
[TBL] [Abstract][Full Text] [Related]
11. The dynamics of Aβ distribution after γ-secretase inhibitor treatment, as determined by experimental and modelling approaches in a wild type rat.
Tai LM; Jacobsen H; Ozmen L; Flohr A; Jakob-Roetne R; Caruso A; Grimm HP
J Pharmacokinet Pharmacodyn; 2012 Jun; 39(3):227-37. PubMed ID: 22481485
[TBL] [Abstract][Full Text] [Related]
12. The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity.
Hook G; Hook V; Kindy M
J Alzheimers Dis; 2011; 26(2):387-408. PubMed ID: 21613740
[TBL] [Abstract][Full Text] [Related]
13. γ-secretase binding sites in aged and Alzheimer's disease human cerebrum: the choroid plexus as a putative origin of CSF Aβ.
Liu F; Xue ZQ; Deng SH; Kun X; Luo XG; Patrylo PR; Rose GM; Cai H; Struble RG; Cai Y; Yan XX
Eur J Neurosci; 2013 May; 37(10):1714-25. PubMed ID: 23432732
[TBL] [Abstract][Full Text] [Related]
14. Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor.
May PC; Dean RA; Lowe SL; Martenyi F; Sheehan SM; Boggs LN; Monk SA; Mathes BM; Mergott DJ; Watson BM; Stout SL; Timm DE; Smith Labell E; Gonzales CR; Nakano M; Jhee SS; Yen M; Ereshefsky L; Lindstrom TD; Calligaro DO; Cocke PJ; Greg Hall D; Friedrich S; Citron M; Audia JE
J Neurosci; 2011 Nov; 31(46):16507-16. PubMed ID: 22090477
[TBL] [Abstract][Full Text] [Related]
15. Combining an amyloid-beta (Aβ) cleaving enzyme inhibitor with a γ-secretase modulator results in an additive reduction of Aβ production.
Strömberg K; Eketjäll S; Georgievska B; Tunblad K; Eliason K; Olsson F; Radesäter AC; Klintenberg R; Arvidsson PI; von Berg S; Fälting J; Cowburn RF; Dabrowski M
FEBS J; 2015 Jan; 282(1):65-73. PubMed ID: 25303711
[TBL] [Abstract][Full Text] [Related]
16. Cisterna magna cannulated repeated CSF sampling rat model--effects of a gamma-secretase inhibitor on Aβ levels.
Shapiro JS; Stiteler M; Wu G; Price EA; Simon AJ; Sankaranarayanan S
J Neurosci Methods; 2012 Mar; 205(1):36-44. PubMed ID: 22226743
[TBL] [Abstract][Full Text] [Related]
17. Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897.
Anderson JJ; Holtz G; Baskin PP; Turner M; Rowe B; Wang B; Kounnas MZ; Lamb BT; Barten D; Felsenstein K; McDonald I; Srinivasan K; Munoz B; Wagner SL
Biochem Pharmacol; 2005 Feb; 69(4):689-98. PubMed ID: 15670587
[TBL] [Abstract][Full Text] [Related]
18. Multiple γ-secretase product peptides are coordinately increased in concentration in the cerebrospinal fluid of a subpopulation of sporadic Alzheimer's disease subjects.
Hata S; Taniguchi M; Piao Y; Ikeuchi T; Fagan AM; Holtzman DM; Bateman R; Sohrabi HR; Martins RN; Gandy S; Urakami K; Suzuki T;
Mol Neurodegener; 2012 Apr; 7():16. PubMed ID: 22534039
[TBL] [Abstract][Full Text] [Related]
19. Effects of gamma-secretase inhibition on the amyloid beta isoform pattern in a mouse model of Alzheimer's disease.
Portelius E; Zhang B; Gustavsson MK; Brinkmalm G; Westman-Brinkmalm A; Zetterberg H; Lee VM; Trojanowski JQ; Blennow K
Neurodegener Dis; 2009; 6(5-6):258-62. PubMed ID: 19955704
[TBL] [Abstract][Full Text] [Related]
20. Dynamics of Aβ42 reduction in plasma, CSF and brain of rats treated with the γ-secretase modulator, GSM-10h.
Hawkins J; Harrison DC; Ahmed S; Davis RP; Chapman T; Marshall I; Smith B; Mead TL; Medhurst A; Giblin GM; Hall A; Gonzalez MI; Richardson J; Hussain I
Neurodegener Dis; 2011; 8(6):455-64. PubMed ID: 21389687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
